The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 10, 2019
Filed:
Jun. 19, 2018
Applicant:
Janssen Pharmaceutica NV, Beerse, BE;
Inventors:
Gilles Bignan, Bridgewater, NJ (US);
Peter J. Connolly, New Providence, NJ (US);
Ian Hickson, Tyne & Wear, GB;
Lieven Meerpoel, Beerse, BE;
Vineet Pande, Vosselaar, BE;
Zhuming Zhang, Hillsborough, NJ (US);
Jonathan Branch, Hatfield, PA (US);
Christian Rocaboy, Murcia, ES;
Luis B. Trabalón Escolar, Murcia, ES;
Assignee:
Janssen Pharmaceutica NV, Beerse, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 491/107 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 409/14 (2006.01); C07D 451/02 (2006.01); C07D 451/06 (2006.01); C07D 487/04 (2006.01); C07D 491/044 (2006.01); C07D 491/048 (2006.01); A61K 9/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/46 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01);
U.S. Cl.
CPC ...
C07D 491/107 (2013.01); A61K 9/0053 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/46 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 451/02 (2013.01); C07D 451/06 (2013.01); C07D 487/04 (2013.01); C07D 491/044 (2013.01); C07D 491/048 (2013.01);
Abstract
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein Rand G are defined herein.